HMGB2-induced calreticulin translocation required for immunogenic cell death and ferroptosis of cancer cells are controlled by the nuclear exporter XPO1.
Fan J, Gillespie KP, Mesaros C, Blair IA., Free PMC Article

The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms.
Vadeikienė R, Jakštys B, Laukaitienė D, Šatkauskas S, Juozaitytė E, Ugenskienė R., Free PMC Article

CircATF6 inhibits hepatocellular carcinoma progression by suppressing calreticulin-mediated Wnt/β-catenin signaling pathway.
Wang YN, Cao D, Liu J, Ren QN, Weng NQ, Zhou YF, Zhang MY, Wang SC, Chen MS, Mai SJ, Wang HY.

Calreticulin regulates the expression of MMP14 and ADAR1 through EIF2AK2 signaling to promote the proliferation and progression of malignant melanoma cells.
Liang L, Wang J, Guo T, Huang L, Wu Y, Xu R, Huang T, Ma B.

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.
Haage TR, Charakopoulos E, Bhuria V, Baldauf CK, Korthals M, Handschuh J, Müller P, Li J, Harit K, Nishanth G, Frey S, Böttcher M, Fischer KD, Dudeck J, Dudeck A, Lipka DB, Schraven B, Green AR, Müller AJ, Mougiakakos D, Fischer T., Free PMC Article

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
Aubin L, Vilas Boas R, Daltro De Oliveira R, Le Brun V, Divoux M, Rey J, Mansier O, Ianotto JC, Pastoret C, Desmares A, Murati A, de Mas V, Tavitian S, Girodon F, Soret Dulphy J, Maslah N, Goncalves Monteiro V, Boyer F, Orvain C, Ranta D, Cayssials É, Le Clech L, Nicol C, Rottier C, Botin Lopez T, Castel B, Rispal P, Beziat G, Bescond C, Laribi K, Benajiba L, Ugo V, Lippert E, Cottin L, Luque Paz D.

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.
Narlı Özdemir Z, İpek Y, Patır P, Ermiş G, Çiftçiler R, Özmen D, Baysal M, Gürsoy V, Yıldızhan E, Güven S, Ercan T, Elibol T, Mersin S, Genç E, Davulcu EA, Karakuş V, Erkut N, Güneş G, Diz Küçükkaya R, Eşkazan AE., Free PMC Article

TMCO1 regulates cell proliferation, metastasis and EMT signaling through CALR, promoting ovarian cancer progression and cisplatin resistance.
Sun G, Gong S, Lan S, He Y, Sun Y, Zhang Z.

[Comparison of Clinical Characteristics of JAK2, CALR and Tri-Negative Driving Mutant Type in Patients with Essential Thrombocythemia].
Li YM, Yang EP, Wang ZQ, Wang DH, Niu JC, Li YJ, Ming J, Sun MQ, Chen Z, Liu WY, Lyu Y, Hu XM.

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms.
Holl K, Chatain N, Krapp S, Baumeister J, Maié T, Schmitz S, Scheufen A, Brock N, Koschmieder S, Moreno-Andrés D., Free PMC Article

Identification and characterization of calreticulin as a novel plasminogen receptor.
Bharadwaj AG, Okura GC, Woods JW, Allen EA, Miller VA, Kempster E, Hancock MA, Gujar S, Slibinskas R, Waisman DM., Free PMC Article

Calreticulin Regulates SARS-CoV-2 Spike Protein Turnover and Modulates SARS-CoV-2 Infectivity.
Rahimi N, White MR, Amraei R, Lotfollahzadeh S, Xia C, Michalak M, Costello CE, Mühlberger E., Free PMC Article

JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
Giraldo-Rincón AI, Naranjo Molina S, Gomez-Lopera N, Aguirre Acevedo D, Ucroz Benavidez A, Gálvez Cárdenas K, Cuellar Ambrosí F, Torres JD, Ospina S, Palacio K, Gaviria Jaramillo L, Muñeton CM, Vasquez Palacio G., Free PMC Article

Calreticulin Expression in Human Carcinomas: A Systematic Review and Meta-Analysis.
Paravani Palacon M, Morandin Ferrisse T, De Oliveira Barbeiro C, Maria Sgavioli Massucato E, Bufalino A., Free PMC Article

Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 CALR-Mutated MPN.
Wang YH, Chen YJ, Lai YH, Wang MC, Chen YY, Wu YY, Yang YR, Tsou HY, Li CP, Hsu CC, Huang CE, Chen CC., Free PMC Article

Unraveling the connection between calreticulin and myeloproliferative neoplasms via calcium signaling.
Jaiswal A, Wang Z, Xudong Z, Ju Z.

Prognostic role of the innate immune signature CD163 and "eat me" signal calreticulin in clear cell renal cell carcinoma.
Anno T, Tanaka N, Takamatsu K, Hakozaki K, Kufukihara R, Baba Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Mikami S, Nishihara H, Mizuno R, Oya M., Free PMC Article

The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells.
Sen Santara S, Lee DJ, Crespo Â, Hu JJ, Walker C, Ma X, Zhang Y, Chowdhury S, Meza-Sosa KF, Lewandrowski M, Zhang H, Rowe M, McClelland A, Wu H, Junqueira C, Lieberman J., Free PMC Article

Effects of calreticulin mutations on cell transformation and immunity.
Desikan H, Kaur A, Pogozheva ID, Raghavan M., Free PMC Article

Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia.
Radjasandirane R, de Brevern AG., Free PMC Article

CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients.
Weir P, Hindley A, Catherwood M, McMullin MF., Free PMC Article

[The Expression and Correlation of miR-195, miR-125 and Calreticulin in Diffuse Large B-Cell Lymphoma].
Li Y, Liu XY, Cui GR, Kong XY, Yang L, Luo JM.

The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience.
Basim Najm M, Jalal SD, Getta HA.

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.
Lilleskare S, Vorland M, Vo AK, Aarsand AK, Reikvam H.

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.
Jutzi JS, Marneth AE, Jiménez-Santos MJ, Hem J, Guerra-Moreno A, Rolles B, Bhatt S, Myers SA, Carr SA, Hong Y, Pozdnyakova O, van Galen P, Al-Shahrour F, Nam AS, Mullally A.